Examining The Intracellular Pathways Regulated By GM-CSF In Macrophages And The Role In Diseases Such Arthritis.
Funder
National Health and Medical Research Council
Funding Amount
$63,567.00
Summary
A protein, termed GM-CSF, has been shown to be important in inflammatory conditions, like rheumatoid arthritis. GM-CSF can modify the properties of a key white blood cell, the macrophage, causing macrophages to produce factors harmful to host tissue. Various therapies are being developed to block GM-CSF, however discovering other drugs that block the intracellular actions of GM-CSF in macrophages are needed. Therefore the molecular pathways governing these actions need to be defined.
Development Of A Highly Potent, Fully Human Anti-GM-CSF Monoclonal Antibody
Funder
National Health and Medical Research Council
Funding Amount
$334,000.00
Summary
Many diseases, such as arthritis, have unwanted inflammatory reactions. Better drugs are needed to control inflammation. A powerful antibody to a significant pro-inflammatory cytokine will be generated; this antibody will be especially designed so that it will not be rejected by patients. Because of its properties it will cost the community less than similar therapeutics. Because inflammatory diseases are common many patients will benefit from our therapeutic.
Structural Biology Of Cytokine Receptor Signalling
Funder
National Health and Medical Research Council
Funding Amount
$3,988,996.00
Summary
This Program will be focused on a group of protein hormones and their receptors, implicated in blood cell cancers and inflammatory diseases and for which current treatments are inadequate. We will determine the mechanism of receptor activation and in particular will seek to link different forms of receptor assembly to different functions. This information will help us develop new drugs with more specificity for certain hormone functions and thus less side-effects.
Towards A Rational Strategy For Osteoarthritis Therapy
Funder
National Health and Medical Research Council
Funding Amount
$945,993.00
Summary
Osteoarthritis is the most common form of arthritis, causing disability and chronic pain, for which there are no adequate treatments. Our laboratory has shown that a particular protein is involved in inflammatory arthritis and pain. Blocking this protein in patients with rheumatoid arthritis is showing success. In this project we will carry out some preclinical studies to determine whether blockade of this protein may also be a therapeutic target for osteoarthritis pain and disease.